Codexis, Inc. (NASDAQ:CDXS) Director Sells $229,283.88 in Stock

Codexis, Inc. (NASDAQ:CDXSGet Rating) Director John J. Nicols sold 35,714 shares of the business’s stock in a transaction on Tuesday, January 24th. The shares were sold at an average price of $6.42, for a total transaction of $229,283.88. Following the transaction, the director now directly owns 823,750 shares in the company, valued at $5,288,475. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Codexis Stock Performance

Codexis stock traded up $0.26 during mid-day trading on Wednesday, reaching $6.61. The stock had a trading volume of 592,520 shares, compared to its average volume of 808,089. The company has a 50-day moving average price of $5.40 and a two-hundred day moving average price of $6.44. Codexis, Inc. has a one year low of $4.21 and a one year high of $22.22.

Codexis (NASDAQ:CDXSGet Rating) last announced its quarterly earnings results on Thursday, November 3rd. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. The company had revenue of $34.47 million for the quarter, compared to analysts’ expectations of $31.41 million. Codexis had a negative net margin of 23.49% and a negative return on equity of 19.59%. Sell-side analysts anticipate that Codexis, Inc. will post -0.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CDXS. Piper Sandler boosted their price objective on shares of Codexis from $22.00 to $23.00 and gave the company an “overweight” rating in a research report on Thursday, January 19th. StockNews.com downgraded shares of Codexis from a “hold” rating to a “sell” rating in a research report on Monday, January 16th. Finally, HC Wainwright reduced their target price on shares of Codexis from $25.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, November 7th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.83.

Hedge Funds Weigh In On Codexis

Hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in Codexis by 20.5% during the 1st quarter. JPMorgan Chase & Co. now owns 52,116 shares of the biotechnology company’s stock valued at $1,075,000 after acquiring an additional 8,870 shares during the period. Bank of New York Mellon Corp lifted its stake in Codexis by 0.7% during the 1st quarter. Bank of New York Mellon Corp now owns 220,879 shares of the biotechnology company’s stock valued at $4,554,000 after acquiring an additional 1,618 shares during the period. US Bancorp DE lifted its stake in Codexis by 517.5% during the 1st quarter. US Bancorp DE now owns 8,380 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 7,023 shares during the period. MetLife Investment Management LLC lifted its stake in Codexis by 55.6% during the 1st quarter. MetLife Investment Management LLC now owns 32,963 shares of the biotechnology company’s stock valued at $680,000 after acquiring an additional 11,784 shares during the period. Finally, BlackRock Inc. lifted its stake in Codexis by 0.7% during the 1st quarter. BlackRock Inc. now owns 5,183,443 shares of the biotechnology company’s stock valued at $106,885,000 after acquiring an additional 38,494 shares during the period. Institutional investors own 93.41% of the company’s stock.

About Codexis

(Get Rating)

Codexis, Inc discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.

Recommended Stories

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.